Alvotech ALVO

NAS: ALVO | ISIN: LU2458332611 17/09/2025

7,930 USD (-0,38%)

(-0,38%) 17/09/2025

Grafiek Alvotech

Grafiek Alvotech

1 dag1d -0,38%
1 week1w -1,25%
1 maand1m -8,75%
3 maanden3m -15,19%
6 maanden6m -30,07%
1 jaar1j -29,07%
5 jaar5j -29,13%

Alvotech in het nieuws

Toon enkel gratis nieuws

4 september 2025 · Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York · Persbericht

21 augustus 2025 · Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea® · Persbericht

20 augustus 2025 · Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia · Persbericht

13 augustus 2025 · Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update · Persbericht

6 augustus 2025 · Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT · Persbericht

10 juli 2025 · Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer · Persbericht

9 juli 2025 · Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland · Persbericht

4 juli 2025 · Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers · Persbericht

2 juli 2025 · Granting of Stock Options and Vesting of Restricted Share Units · Persbericht

1 juli 2025 · Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol) · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe